Literature DB >> 11686289

Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001.

.   

Abstract

On October 8, 2000, an outbreak of an unusual febrile illness with occasional hemorrhage and significant mortality was reported to the Ministry of Health (MoH) in Kampala by the superintendent of St. Mary's Hospital in Lacor, and the District Director of Health Services in the Gulu District. A preliminary assessment conducted by MoH found additional cases in Gulu District and in Gulu Hospital, the regional referral hospital. On October 15, suspicion of Ebola hemorrhagic fever (EHF) was confirmed when the National Institute of Virology (NIV), Johannesburg, South Africa, identified Ebola virus infection among specimens from patients, including health-care workers at St. Mary's Hospital. This report describes surveillance and control activities related to the EHF outbreak and presents preliminary clinical and epidemiologic findings.

Entities:  

Mesh:

Year:  2001        PMID: 11686289

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  52 in total

1.  A global network for early warning and response to infectious diseases and bioterrorism: applied epidemiology and training programs, 2001.

Authors:  Hardeep S Sandhu; Christopher Thomas; Peter Nsubuga; Mark E White
Journal:  Am J Public Health       Date:  2003-10       Impact factor: 9.308

2.  Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences.

Authors:  John Misasi; Kartik Chandran; Jin-Yi Yang; Bryden Considine; Claire Marie Filone; Marceline Côté; Nancy Sullivan; Giulia Fabozzi; Lisa Hensley; James Cunningham
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

3.  Understanding the dynamics of Ebola epidemics.

Authors:  J Legrand; R F Grais; P Y Boelle; A J Valleron; A Flahault
Journal:  Epidemiol Infect       Date:  2006-09-26       Impact factor: 2.451

Review 4.  Live neonates born to mothers with Ebola virus disease: a review of the literature.

Authors:  J M Nelson; S E Griese; A B Goodman; G Peacock
Journal:  J Perinatol       Date:  2015-12-10       Impact factor: 2.521

5.  Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies.

Authors:  Eri Nakayama; Ayaka Yokoyama; Hiroko Miyamoto; Manabu Igarashi; Noriko Kishida; Keita Matsuno; Andrea Marzi; Heinz Feldmann; Kimihito Ito; Masayuki Saijo; Ayato Takada
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

6.  A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.

Authors:  Julie E Martin; Nancy J Sullivan; Mary E Enama; Ingelise J Gordon; Mario Roederer; Richard A Koup; Robert T Bailer; Bimal K Chakrabarti; Michael A Bailey; Phillip L Gomez; Charla A Andrews; Zoe Moodie; Lin Gu; Judith A Stein; Gary J Nabel; Barney S Graham
Journal:  Clin Vaccine Immunol       Date:  2006-09-20

7.  Models of epidemics: when contact repetition and clustering should be included.

Authors:  Timo Smieszek; Lena Fiebig; Roland W Scholz
Journal:  Theor Biol Med Model       Date:  2009-06-29       Impact factor: 2.432

8.  High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.

Authors:  Pierre Becquart; Nadia Wauquier; Tanel Mahlakõiv; Dieudonné Nkoghe; Cindy Padilla; Marc Souris; Benjamin Ollomo; Jean-Paul Gonzalez; Xavier De Lamballerie; Mirdad Kazanji; Eric M Leroy
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

9.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

10.  Field Epidemiology Training Programmes in Africa - Where are the Graduates?

Authors:  David Mukanga; Olivia Namusisi; Sheba N Gitta; George Pariyo; Mufuta Tshimanga; Angela Weaver; Murray Trostle
Journal:  Hum Resour Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.